Collaboration Commences

05 July 2007

LiDCO, the UK based, AIM-quoted cardiovascular monitoring company, is pleased to announce the commencement of it marketing collaboration with Becton Dickinson Limited ("BD"). The start of this exclusive UK collaboration will begin with the joint promotion of the combined critical care products portfolio at the 6th Evidence Based Peri-Operative Medicine Conference for the High-Risk Surgical Patient in London.

BD is a leading global medical technology company (see www.bd.com). The collaboration, as announced in June, involves the joint marketing of certain critical care products sold by BD Medical - Medical Surgical Systems in selected UK hospitals where LiDCO has existing sales and customer relationships.

Dr Terry O'Brien, Chief Executive of LiDCO, commenting on this joint promotion stated:

"Our partnership with BD means that we are now able to offer UK hospitals a broader and more comprehensive portfolio of products. We have already shown that use of our technology can reduce surgical complications and the cost of such care by an average of £4,800 per patient treated. The focus of this meeting is to highlight ways of improving surgical outcomes. It is therefore is an excellent opportunity for us to present to the UK Hospital representatives who are attending the compelling clinical and business case for the full adoption of our combined product offering. If adopted nationally, this could equate to a saving of £500 million per annum for the NHS."

About LiDCO Group Plc

LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO's technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. For more information please see www.lidco.com.

Background to the recently published clinical trial: Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial Critical Care 2005, 9:R687-R693

A major trial at St George's Hospital, London, using LiDCO's minimally invasive monitoring technology, revealed the following:

a) Savings in the cost of treating patients amounting to an average of 12 days less spent in the hospital saving approximately £4,800 per patient. Extrapolated nationally, this would equate to a saving of £500 million per annum for the NHS

b) The savings in cost and hospital days were associated with a significant reduction in medical complications (particularly infections - which were halved) through the use of LiDCO's minimally invasive technology to improve tissue oxygen levels following surgery.

The Company's manufacturing facility is in Hoxton, London and its current products are:

* LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume;

* LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accurately determine cardiac output in a minimally-invasive manner.

* LiDCOview - software product for use on a PC: designed to aide clinical audit, teaching and research activities.

* LiDCOlive - software product in development for the remote display of hemodynamic monitoring parameters derived through use of the LiDCOplus monitor.

Distribution Network:

The Company has now achieved registration of its products in 14 markets in Europe, the USA, Brazil, South Korea and Japan. It sells direct in the UK and USA, and elsewhere through a worldwide network of specialty critical care distributors.